These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26850580)

  • 1. [Clarifying some concepts and clinical significance of refractory or recurrent neovascular age-related macular degeneration].
    Zhao J; Sun X
    Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):804-7. PubMed ID: 26850580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.
    Broadhead GK; Hong T; Chang AA
    Acta Ophthalmol; 2014 Dec; 92(8):713-23. PubMed ID: 24925048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Schachat AP
    Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
    [No Abstract]   [Full Text] [Related]  

  • 4. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
    Yang S; Zhao J; Sun X
    Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related macular degeneration: using morphological predictors to modify current treatment protocols.
    Ashraf M; Souka A; Adelman RA
    Acta Ophthalmol; 2018 Mar; 96(2):120-133. PubMed ID: 29130626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
    Fauser S; Viebahn U; Muether PS
    Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy for the treatment of neovascular age-related macular degeneration.
    Englander M; Kaiser PK
    Curr Opin Ophthalmol; 2013 May; 24(3):233-8. PubMed ID: 23429601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferred therapies for neovascular age-related macular degeneration.
    Lally DR; Gerstenblith AT; Regillo CD
    Curr Opin Ophthalmol; 2012 May; 23(3):182-8. PubMed ID: 22450218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining response to anti-VEGF therapies in neovascular AMD.
    Amoaku WM; Chakravarthy U; Gale R; Gavin M; Ghanchi F; Gibson J; Harding S; Johnston RL; Kelly SP; Lotery A; Mahmood S; Menon G; Sivaprasad S; Talks J; Tufail A; Yang Y
    Eye (Lond); 2015 Jun; 29(6):721-31. PubMed ID: 25882328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
    Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
    Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration.
    Vaze A; Fraser-Bell S; Gillies M
    Acta Ophthalmol; 2014 Dec; 92(8):e697-8. PubMed ID: 24750589
    [No Abstract]   [Full Text] [Related]  

  • 12. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Long Term Follow-Up of Visual Acuity After anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration.
    Guex-Crosier Y
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):366. PubMed ID: 25902076
    [No Abstract]   [Full Text] [Related]  

  • 14. Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age-related macular degeneration.
    Wickremasinghe S; Abedi F; Sandhu SS; Guymer R
    Clin Exp Ophthalmol; 2013 Nov; 41(8):723-6. PubMed ID: 24152187
    [No Abstract]   [Full Text] [Related]  

  • 15. Recalcitrant neovascular macular degeneration after anti-VEGF therapy: an ongoing challenge.
    Puliafito CA
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(2):109. PubMed ID: 23510034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
    Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A
    Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current concepts in managing wet AMD suboptimally responsive to anti-VEGF therapy.
    Major JC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(3):225-6. PubMed ID: 23676221
    [No Abstract]   [Full Text] [Related]  

  • 18. Response of Pigment Epithelial Detachment to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration.
    Cho HJ; Kim KM; Kim HS; Lee DW; Kim CG; Kim JW
    Am J Ophthalmol; 2016 Jun; 166():112-119. PubMed ID: 27048998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neovascular age-related macular degeneration.
    Veritti D; Sarao V; Lanzetta P
    Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
    Feng L; Hu JH; Chen J; Xie X
    J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.